TNTomohiro Nishi

Tomohiro Nishi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tomohiro Nishi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 February 2013
      • Vol. 40  (2) , 245-7

    [An autopsy case of unresectable colon cancer who developed lung injury by cetuximab].

    by Junko Uemoto, Yasuo Hamamoto, Kei Onodera, Tomohiro Nishi, Etsuko Warita, Yasuhiro Yamanaka, Nobuo Hoshi, Kaoru Hirabayashi, Sayuri Hoshi, Seiji Igarashi

    We report the case of a woman in her 60s with unresectable advanced colon cancer. After the first course of cetuximab as second-line therapy, she had developed drug-induced lung injury. Steroid pulse therapy had been ineffective, and she died of respiratory failure on day 9. The pathological examination of autopsy lung specimens revealed diffuse alveolar damage(DAD). Details of the cetuximab-induced lung injury are unclear. However, in 3 previous reports of lung injury by cetuximab, the postmortem findings were similar to this case. We concluded that DAD seems to be one of the pathological features of lung injury caused by cetuximab.

    • 1 December 2012
      • Vol. 39  (13) , 2553-5

    [A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy].

    by Tomohiro Nishi, Yasuo Hamamoto, Junko Uemoto, Kei Onodera, Etsuko Warita, Yasuhiro Yamanaka

    Trastuzumab is the first molecular-target medicine for gastric cancer in acknowledgment of the effectiveness and safety in a randomized controlled trial for the HER2-positive gastric cancer. The HER2-positive rate of gastric cancer tends to be high for a well-differentiated adenocarcinoma. We report a case of HER2-positive scirrhous gastric carcinoma we treated, for whom a complete response was obtained by trastuzumab combination therapy. He was a 62-year-old man. In April, 2006, he was diagnosed with metastatic scirrhous gastric carcinoma(mainly poorly-differentiated adenocarcinoma). We become clear with HER2 strong positive in a pathology tissue and started capecitabine+cisplatin+trastuzumab therapy. We confirmed the disappearance of the lesion at the 10th cycle and judged it to be a complete response. The HER2 of advanced gastric cancer must be screened immediately without asking patients for their background or their clinical and pathologic features.

    • 1 December 2012
      • Vol. 39  (13) , 2557-60

    [Modified FOLFOX6(mFOLFOX6)in metastatic colorectal carcinoma patients with poor performance status].

    by Tomohiro Nishi, Yasuo Hamamoto, Junko Uemoto, Kei Onodera, Etsuko Warita, Yasuhiro Yamanaka

    Because mFOLFOX6 has few contraindications, it is useful for poor performance status(PS)cases. However, in Japan, there are some reports that the dose is reduced easily. We retrospectively examined the safety/usefulness of the full dose mFOLFOX6(first-line)for advanced colon cancer patients with poor PS. Four of five cases had improved PS. The response rate was 60%. Grade 3/4 adverse events were infection, leukopenia, and neutropenia. Treatment-related deaths within 60 days of starting treatment were absent. Full-dose mFOLFOX6 for poor PS may be beneficial. However, we must consider the increased risk of adverse events.


    • 1 May 2011
      • Vol. 38  (5) , 831-3

    [A case of metastatic colon cancer in which repetition of standard treatment proved effective].

    by Tomohiro Nishi, Yasuo Hamamoto, Etsuko Warita, Yasuhiro Yamanaka, Tosuke Kitamura, Takashi Matsui, Kenjiro Kotake

    In palliative chemotherapy, a focus on palliative treatment is recommended in cases that are unresponsive to multiple drugs. Careful judgment is needed, however, because when treatment is inadequate, cases that are considered to be unresponsive may include some in which chemotherapy would be effective. We treated a patient with metastatic colon cancer who was judged to be unresponsive to multiple drugs at another hospital, yet repetition of standard therapy proved effective. We report this case as an instructive example of the importance of maintaining dose intensity. The patient was a 60-year-old man. Lung metastasis appeared after he had undergone proctectomy and received adjuvant chemotherapy by his previous doctor. Low-dose intensity IFL therapy, FOLFOX4 therapy (once a month), and FOLFIRI therapy (once only) had been performed, but the patient's condition worsened and he was referred to our hospital. This case could not be considered unresponsive to multiple drugs because the treatment had been insufficient, and so we restarted FOLFIRI treatment with the international standard dose and obtained control of the disease. Treatment was then continued, and the patient died 2 years and 11 months after he was first examined at our hospital. Simple palliative treatment alone should not be given unthinkingly when patients are referred for outpatient palliative care. Full consideration of the dosing and schedule is needed.

    • 1 April 2011
      • p. 545-9

    [Treatment with CPT-11 based on the UGT1A1 genetic polymorphism].

    by Tomohiro Nishi, Tomomi Komaki, Yasuo Hamamoto

  • Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma

    by Tomohiro Nishi, Yasuo Hamamoto, Etsuko Warita, Junko Miyamoto, Noriyuki Akutsu, Yasuhiro Yamanaka, Michitaka Nagase, Hirofumi Fujii

    When applying the topoisomerase inhibitor irinotecan (CPT) with the infusional fluorouracil/levofolinate (FOLFIRI) ± bevacizumab chemotherapy regimen in cases of advanced colorectal carcinoma, the international standard dose for CPT is 180 mg/m2. Despite this, 150 mg/m2 CPT is widely prescribed and is the maximum dosage covered by Japanese health insurance. Consequently, the safety of dosing at the international standard has not been tested comprehensively and the efficacy of FOLFIRI in Japan may be underestimated. To evaluate the safety of FOLFIRI (+bevacizumab) in clinical practice using international standards, we reviewed medical records of 53 patients who received FOLFIRI (+bevacizumab) with CPT 180 mg/m2 as first-line treatment between September 2004 and August 2009. The primary endpoint of the study was to measure the relative dose intensity (RDI) of CPT after four courses. The secondary endpoint was to assess treatment completion rate, adverse events, response rate, progression-free survival (PFS) and overall survival (OS) among all patients. The RDI and the treatment completion rate were 88.9% and 69.8%, respectively, in the 53 patients. Accompanying grade 3 or 4 adverse events included neutropenia (35.8%), febrile neutropenia (7.5%), and diarrhea (3.8%). Supportive care managed all toxicity symptoms. Median durations for PFS and OS were 10.3 and 26.5 months, respectively. FOLFIRI (+bevacizumab) with the international standard dose of CPT is feasible in clinical practice. In order to minimize deviation of the Japanese regimen from global best practice, international dose standards should be followed.